Precision proteomics company Alamar Biosciences has raised $100 million in an oversubscribed series C financing round, with a second close of an additional $28 million anticipated within the next 30 days.
The round was led by Sands Capital and included participation from both new and existing investors.
Concurrent with the financing, Ian Ratcliffe, an executive managing partner of Sands Capital, has joined Alamar’s board of directors.
In a statement, the Fremont, CA-based firm noted that this new capital infusion brings Alamar’s total funding to date to nearly $250 million. The company said that it plans to use the funds to accelerate the commercialization of its Nulisa proteomic platform, growing commercial and customer support teams, market adoption, and expanding the product menu.
Nulisa is a proteomic liquid biopsy platform that enables focused analysis of validated biomarkers and highly multiplexed profiling of up to thousands of proteins. The technology uses a sequential capture-and-release method to purify the immune complex, improving signal-to-noise ratio with corresponding increases in sensitivity and dynamic range compared to traditional immunoassay methods, according to the firm.
In early January, Alamar launched its ARGO HT System for high-sensitivity protein analysis of biofluids and the Nulisaseq Inflammation Panel 250 for deep profiling of immune response.
